As of January 2013 apceth has entered the second round of funding for the development of its first cancer therapeutic based on patient's own modified adult mesenchymal stem cells running under the portfolio name Agenmestencel-T. In December 2012 apceth has successfully concluded the first 2.5-year round of funding through the Federal Ministry of ... (more)
http://www.biospace.com/news_story.aspx?StoryID=286628&full=1
http://www.biospace.com/news_story.aspx?StoryID=286628&full=1
No comments:
Post a Comment